The Utility of Biofire Filmarray in Evaluation of Entero Pathogens Triggers in Patients With Chronic Diarrhea
NCT ID: NCT04269174
Last Updated: 2020-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
50 participants
OBSERVATIONAL
2020-02-29
2021-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The standard evaluation of patients with chronic diarrhea that begins with a detailed history, a careful physical examination and then basic diagnostic tests is critical for optimal treatment and prevention. Initially, thought needs to exclude several other possibilities as (a) fecal incontinence masquerading as diarrhea, (b) iatrogenic diarrhea due to drugs, surgery, or therapeutic radiation, (c) chronic infections, and (d) irritable bowel syndrome with diarrhea (IBS-D).
The detection of a broad array of potentially offending agents has traditionally required a combination of microbiologic approaches, including bacterial culture, antigen detection, microscopy, and polymerase chain reaction (PCR). The new multiplex PCR-based panels have several advantages over conventional methods including (i) reduced sample volume requirements, (ii) broad coverage without the need to select specific tests, (iii) enhanced ability to detect coinfections (iv) increased sensitivity and specificity as high as 97-100% and (v) higher throughput.The food and drug administration (FDA) cleared and recommended the use of FilmArray GI panel (BioFire Diagnostics), which targets 22 analytes (bacteria with bacterial toxin, viruses, and parasites)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Magnification Endoscopy and Electronic Chromoendoscopy in Patients With Inflammatory Bowel Disease
NCT03536091
Chronic Diarrhea Owing to Underlying Microscopic Colitis
NCT06530836
Intestinal Bacteria and Ocular Inflammatory Disease
NCT01859299
Identifying Saliva Markers in Inflammatory Bowel Disease
NCT01590043
Novel Biomarkers in Inflammatory Bowel Disease
NCT03833310
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
• Routine laboratory investigation: Complete blood picture and differential WBCs count, liver, kidney function tests, RBG, Na, K, CRP, ESR.
• Microbilogical Investigations:
To ensure that good specimens are provided for examination, it is important to note the following:
* A sterile clean dry container must be used for the collection of fecal samples.
* The specimen should be brought to the lab as soon as possible.
* The specimen container should be clearly labeled with the patient's name, date, and time of passage of the specimen.
A) Conventional methods:
Stool samples will be cultured on Selenite broth then subcultured on blood agar, chocolate agar, MacConkeys agar, Sorbitol MacConkys agar: Xylose Lysine Deoxycholate agar (XLD) ,Sabouraud dextrose agar (SDA), blood agar with 10um/ml ampicillin , Cambylobacter CVA agar plates.
1. Identification of the bacterial organism:
Pure colonies of isolated microorganisms were identified by:
* Morphology on agar.
* Gram stain film was made from the growth to identify morphology of the organism.
* Biochemical reactions tests.
2. Detection of antibiotic sensitivity pattern according to CLSI 2019 by disc diffusion method
3. Confirmation of results by automated microbial system VITEK 2Compact.
B) Multiplex PCR: for Identification of different causative organisms by Biofire microarray (BioMerieux,France)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shaimaa Mahmoud Abd El-mouez
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shaimaa Mahmoud Abd El-mouez
Principe investigator
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Maharshak N, Ringel Y, Katibian D, Lundqvist A, Sartor RB, Carroll IM, Ringel-Kulka T. Fecal and Mucosa-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome. Dig Dis Sci. 2018 Jul;63(7):1890-1899. doi: 10.1007/s10620-018-5086-4. Epub 2018 May 17.
Buss SN, Leber A, Chapin K, Fey PD, Bankowski MJ, Jones MK, Rogatcheva M, Kanack KJ, Bourzac KM. Multicenter evaluation of the BioFire FilmArray gastrointestinal panel for etiologic diagnosis of infectious gastroenteritis. J Clin Microbiol. 2015 Mar;53(3):915-25. doi: 10.1128/JCM.02674-14. Epub 2015 Jan 14.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AssiutU The utility of Biofire
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.